Back to search results

Longitudinal Imaging in Progressive Apraxia of Speech

This study is looking at how changes in the brain, seen through imaging, relate to the progression of speech and language problems in people with neurodegenerative apraxia of speech (AOS). AOS is a disorder that affects how you produce speech. Researchers will use a drug called AV-1451 to help them see "Tau burden" in the brain, which is a protein linked to certain brain diseases. You might be able to join if you are 18 or older and have been diagnosed with neurodegenerative AOS at Mayo Clinic. People with other illnesses that could explain their speech problems, like a stroke, cannot join. The study aims to see how changes in brain images over about 1-2 years connect with changes in your speech and other abilities during that time. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for approximately 1-2 years after baseline imaging to measure changes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01818661

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Recruiting
PHASE4Ages 18+InterventionalDiagnostic
Mayo Clinic
~50 participants
Updated 2025-11-12 on ClinicalTrials.gov
What's tested:AV-1451

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
measurement of longitudinal change in neuroimaging and the correlation between change on serial imaging measures and concurrent change on longitudinal measures of clinical performance in neurodegenerative AOS with or without non-fluent aphasia (NFA)
Measured over approxiamtely 1-2 years after baseline imaging

Conditions

PPA
Non-fluent Aphasia
Apraxia of Speech
Primary Progressive Non-fluent Aphasia
Primary Progressive Aphasia

Explore related trials

Apraxic aphoniaPrimary Progressive Aphasia

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Jennifer Whitwell, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Sarah Boland, CCRP
[email protected]
507-284-3863
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded.
Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.
Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).
Subjects will also be excluded if they do not have an informant, or do not consent to research.

What this trial measures

  • measurement of longitudinal change in neuroimaging and the correlation between change on serial imaging measures and concurrent change on longitudinal measures of clinical performance in neurodegenerative AOS with or without non-fluent aphasia (NFA)approxiamtely 1-2 years after baseline imaging